mdr-1、c-erbB-2和bcl-2基因表达与乳腺癌耐药性的研究

Studies on mdr-1、c-erbB-2 and bcl-2 Gene Expression and Human Breast Carcinoma Resistance

目的 探讨 mdr- 1、c- erb B- 2和 bcl- 2作为乳腺癌耐药相关基因常规检测的可行性 ,并观察三种基因与肿瘤发展预后的关系 ,以期指导治疗。方法 应用 S- P法免疫组化技术对 43例疗前乳腺癌组织标本的常规切片进行检测。结果 (1 ) c- erb B- 2和 bcl- 2以中高度表达为主 ,mdr- 1则以低表达或无表达为主。 (2 )复发组与未复发组相比 ,mdr- 1表达有显著性差异 (P<0 .0 5 ) ,c-erb B- 2和 bcl- 2则无显著性差异 (P>0 .0 5 )。 (3)复发病例中 c- erb B- 2以高表达为主 ,bcl- 2均为低表达或无表达。结论 三种基因可作为乳腺癌耐药相关基因而用于临床检测并可为术后治疗及判断预后提供依据。

Objective To study the availability that detect mdr 1?c erbB 2 and bcl 2 as the resistance gene in breast cancer patients. To observe the relationship among the gene expression and the advance prognosis of carcinoma.Methods Routine section preparation form 43 cases pretreat ment breast cancer patients were measured in SP Immumnohistochemical method.Results (1) c erbB 2 and bcl 2 express middle or high level in multiple cases, but mdr 1 express low level or negative . (2) To comparative the recurrence group and irrecurrence group. It's shows that the expression mdr 1 is significient difference ( P < 0.05 ), but the expression c erbB 2 and bcl 2 express low level or negative( P >0.05) .(3) In the recurrence patients c erbB 2 express high level in mul tiple cases. Bcl 2 express low level or negative . Conclusion These three gene can be used clinical as gene correlated with human breast cancer resistance. They may offer objective gist for making treatment and judging prognosis.